IMC supports the creation of a Pan Canadian Genomics Strategy (PCGS) to help Canada advance its international leadership and increase capacity in genomics through commercialization and adoption.
Our resource hub to discover reports, policy papers and other forms of informative content
Use this tool to search for brand name drugs to view their current negotiation status.
Optimizing Patient Access to Precision Therapies: Preparing for the Emerging Era of Advanced Testing
This policy note characterizes Canada’s current testing infrastructure and its limitations, which include that it hinders current and future patient access to the best available treatments.
Canadians relying on public insurance plans face significant delays accessing new medicines. This graph breaks down the sequential approval and listing process, and demonstrates how long it takes Canadians to access innovative medicines.
Clinical trials provide Canadian oncology patients with earlier access to new, innovative cancer treatments. But changes pending to the PMPRB will make the Canadian pharmaceutical market less attractive for investment.
Many products coming to market are poorly served by traditional negotiation approaches. This document describes innovative agreements being used in jurisdictions outside Canada. We prepared it to guide discussions with the pCPA Governing Council on the merits of jointly developing an innovative agreements framework.
The 2021 Cost Drivers report highlights the consistent annual cost growth in the Canadian private drug benefits market and outlines factors that contribute to price increases.
The COVID-19 pandemic has graphically demonstrated the need for a better life sciences environment in Canada. This document outlines the industry’s recommendations for building a thriving sector.
IMC and and BIOTECanada write to Suzanne McGurn with joint input on the current CADTH process consultation.